Members of the CLS’ Board of Directors and management have entered into declarations of intent to subscribe for new B-shares in connection with the exercise of warrants of series TO 5 B
Lund, Sweden – Members of the Board of Directors and management of Clinical Laserthermia Systems AB's ("CLS" or "Company") have entered into declarations of intent to exercise all of their warrants of series TO 5 B to subscribe for new B-shares in the Company's upcoming warrant exercise, corresponding a total of approximately SEK 200,000.Each warrant of series TO 5 B entitles the holder to subscribe for one (1) new B-share in CLS to the subscription price that has been set at SEK 0.46 per share. Members of the Board of Directors and management of the Company have entered into